Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.51 |
| ▸ | CCKBR | P32239 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390474 | 0.91 | CCKBR (0.50) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL12390481 | 0.90 | CCKBR (0.48) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL13061002 | 0.89 | CCKBR (0.55) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL2263593 | 0.89 | TRPV1 (0.55) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL12390483 | 0.89 | TRPV1 (0.55) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL11982407 | 0.88 | TRPV1 (0.56) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL14064501 | 0.86 | TRPV1 (0.53) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL2267811 | 0.82 | CCKBR (0.54) | TRPV1CCKBRMEN1LMNAALB | |
| SCHEMBL14707952 | 0.82 | TRPV1 (0.48) | TRPV1CCKBR | |
| SCHEMBL13061384 | 0.82 | CCKBR (0.39) | TRPV1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | TRPV1 3140/4885CCKBR 4482/4885MEN1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.